

Dr. Nooka will not be participating in the meeting noted in the waiver. This waiver is null and void.



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Ajay Nooka, MD, MPH

Committee: Oncologic Drugs Advisory Committee

Meeting Date: April 12, 2024

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On April 12, 2024, the Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Work as consultant/advisor	(b) (4), affected firm	\$0 - \$5,000 per year to Dr. Nooka
II. Other Imputed Interests		
Contracts/grants	Employer's research funded by Janssen Pharmaceuticals, affected firm	\$50,000 - \$100,000 per year to Emory University

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_\_3/25/2024\_\_\_\_\_  
Date